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Tick-borne encephalitis is a viral disease affecting the central nervous system. It is 
endemic in Switzerland with 200–250 notified cases annually. Active immunization is 
effective for persons in all age groups. Vaccine failure is rare, in particular after a com-
pleted vaccination course. Here, we describe the case of 67-year-old man with a fatal 
outcome despite vaccination. The diagnosis was confirmed by extensive postmortem 
analyses. The diagnostic challenges of vaccine failure in tick-borne encephalitis and the 
dynamics of the immune response in vaccination breakthrough are discussed.
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INtRoDUCtIoN
Tick-borne encephalitis virus (TBEV) can cause severe meningoencephalitis with substantial mor-
bidity. The vaccine against TBEV has shown high efficacy (1). Vaccine failures—as presented in 
this case with a fatal outcome—are rare, in particular when the vaccine series has been completed. 
Vaccine failures often cause diagnostic challenges and hence are associated with delayed diagnosis. 
The clinical, electrophysiological, and neuroimaging evolution of this case, which included serial 
serum and cerebrospinal fluid (CSF) samples and brain biopsy, together with postmortem analyses, 
may yield insights into the dynamics of the immune response in TBE vaccination breakthrough.
Case RepoRt
The clinical diagnosis of meningitis was raised in a 67-year-old farmer when he presented with 
headaches, fever, nausea, and vomiting. The symptoms started 1 day prior to presentation. He was 
treated intravenously with ceftriaxone, amoxicillin, and acyclovir. His laboratory studies revealed 
an elevated white blood cell (WBC) count of 15,600/μL with 4.5% bands. His C-reactive protein 
level was 19.2 mg/L, and his erythrocyte sedimentation rate was 13 mm/h. Blood and urine culture 
yielded no growth of microorganisms. A computed tomography (CT) scan of the head showed no 
pathologic findings. CSF analysis revealed a WBC count of 244/μL (46/μL neutrophils and 198/μL 
lymphocytes), a protein level of 0.38  g/L and a glucose level of 3.86  mmol/L (in comparison to 
glucose in serum of 6.51 mmol/L and a CSF-serum ratio of 0.6). The results of a CSF culture for 
bacteria, fungi, and mycobacteria were negative. Polymerase chain reaction (PCR) analyses for her-
pes simplex virus (HSV) 1 and 2 and varicella zoster virus (VZV) in CSF were negative. Serological 
tests were negative for Borrelia burgdorferi, but reactive for TBEV (IgG positive, IgM negative). 
The results were consistent with his vaccine status, as he had been vaccinated against TBEV at 19, 
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18, and 5 months prior to referral. During the next 3 days, his 
encephalitic symptoms progressed. The patient showed persistent 
fever and was then transferred to our tertiary care hospital for 
further treatment.
The patient had a medical history of rheumatoid arthritis, 
for which he was treated with prednisone (5 mg once daily) and 
methotrexate (20 mg once weekly). These compounds were not 
continued after first presentation. Of note, only the last vaccine 
against TBEV was administered while he was under immunosup-
pressive treatment. He had no significant family history, recent 
travel, or allergies.
On admission to our hospital, his body temperature was 
38.8°C, he was disoriented and somnolent [Glasgow Coma Score 
(GCS) 12], and he showed neck stiffness, increased tonicity of the 
upper and lower extremities, increased jerks of the lower limbs, 
and myoclonic movements.
Repeated CSF analysis revealed a WBC count of 36/μL 
(99% lymphocytes) and repeated PCR tests for HSV 1, HSV 2, 
VZV, cytomegalovirus, enterovirus, and cryptococcal antigen 
remained negative. Screening for Mycoplasma antibodies and for 
vasculitis via multiple blood tests was negative, and a search for 
paraneoplastic causes by a CT scan of the chest and abdomen 
showed no pathologic results. Antimicrobial agents were stopped 
after microbiological investigations returned negative results.
Multiple electroencephalograms (EEGs) showed generalized 
slow-wave activity (Figure 1A). Within 3 days, the patient became 
comatose and his GCS fell to 4. He developed a syndrome of inap-
propriate antidiuretic hormone secretion and severe peripheral 
axonal neuropathy. The initially preserved oculocephalic reflex 
with positive doll’s eye phenomenon was soon abolished, and his 
GCS decreased to 3. The initial cranial magnetic resonance imag-
ing (MRI) scan demonstrated no abnormal findings (Figure 2A) 
nor did the subsequent cranial CT scan on days 7 and 10. On day 
9, periods of rhythmic epileptiform signal transients occurred 
with bifrontal localization. Antiepileptic medication was started 
with levetiracetam. Subsequent EEGs showed further slowing 
of background activity, with the appearance of triphasic signals 
(Figure 1B). Electroneuromyography demonstrated the absence 
of motor responses, even upon maximal electrical nerve stimula-
tion, but the presence of somatosensory evoked potentials. The 
cranial MRI scan on day 16 showed slight hyperintensity in the 
region of the left lateral thalamus (Figures 2B–D).
An open brain biopsy on day 15 showed scant infiltration of the 
cerebral cortex by CD3-positive T-lymphocytes and microglial 
activation (Figure 3). Immunostaining for HSV 1 and HSV 2 was 
negative. The findings were consistent with viral encephalitis with 
consecutive immune response or cellular infiltration in cerebral 
parenchyma due to an autoimmune disease. However, neither 
treatment with corticosteroids nor with plasmapheresis resulted 
in significant improvement of brain function or peripheral nerve 
function.
On the basis of a high risk for persistent tetraplegia (extensive 
axonal peripheral motor denervation on electromyography with 
absence of motor responses on electrical stimulation) and for 
lifelong ventilator dependence and a poor cerebral prognosis, 
his family elected to provide comfort measures only. Four weeks 
after the onset of symptoms, the patient died. Shortly before the 
patient’s demise, IgM antibodies against West Nile virus (WNV) 
were detected in the serum.
MetHoDs aND ResULts
West Nile virus is not endemic in Switzerland (i.e., to the best 
of our knowledge, no cases have ever been reported). Thus, 
cross-reactivity with another flavivirus was the most plausible 
hypothesis to explain the detection of anti-WNV-IgM in serum. 
Therefore, frozen samples of serum and CSF, as well as CNS tissue 
samples, were reanalyzed postmortem.
analyses of serum samples
Serum was reanalyzed with a flavivirus immune fluorescence 
assay (BIOCHIP flavivirus-mosaic 2 immunofluorescence 
assay; EUROIMMUN, Germany) and revealed high anti-TBEV 
antibody titers that cross-reacted with WNV, yellow fever virus, 
Japanese encephalitis virus, and dengue virus. TBEV IgG and IgM 
levels were retrospectively determined simultaneously in serum 
samples obtained on days 9 and 22 after onset of symptoms by per-
forming an enzyme-linked immunosorbent assay (ELISA) with 
the Virotech Kit (FSME/TBE IgG/IgM ELISA; Sekisui Virotech, 
Germany). There was a 138-fold increase in anti-TBEV IgM levels 
and a 103-fold increase in anti-TBEV IgG levels between days 9 
and 22. Avidity testing of the anti-TBEV IgG antibodies revealed 
highly avid anti-TBEV IgG antibodies, implying a secondary 
immune response. Serum obtained on day 4 was reanalyzed with 
real-time reverse transcriptase (RT)-PCR for WNV and TBEV; 
in addition, pan-flavivirus PCR was performed. The results of all 
assays were negative.
analyses of CsF samples
Massive intrathecal IgM (92%) and IgG (73%) production could 
be documented in the CSF obtained on day 22 by using the scheme 
of Reiber and Felgenhauer. Subsequently, TBEV-specific intrathe-
cal IgM and IgG antibody synthesis was proven by highly elevated 
CSF/serum antibody indices. CSF obtained on day 4 was also 
reanalyzed with RT-PCR for WNV and TBEV, and a pan-flavivirus 
PCR was performed. The results of these assays were also negative.
Histopathology
At autopsy, the brain showed marked generalized edema. 
Histologically, there was lymphocytic infiltration of the hip-
pocampi, basal ganglia brain stem, Purkinje cell layer of the 
cerebellar cortex, anterior horns of the spinal cord, and leptome-
ninges (Figure 4). Neurogenic atrophy was confirmed in the left 
psoas muscle. RT-PCR for the detection of TBEV was performed 
on postmortem samples from the cerebellum and spinal cord. 
High copy numbers of viral RNA were found in both samples. 
Immunohistochemical analysis for the demonstration of TBEV 
antigen was performed on tissue samples of the spinal cord and 
the cortical cerebellum. Paraffin sections (6 µm) were stained by 
using the horseradish peroxidase method (EnVision™; Dako) 
and a previously characterized rabbit polyclonal antibody gener-
ated against the Hochosterwitz TBEV isolate (kindly donated by 
Prof. Franz X. Heinz, University of Vienna, Austria) (2). Antigen 
retrieval was performed by using the microwave/citrate buffer 
FIGURe 1 | (a) Electroencephalogram (EEG) (bipolar display) showing epileptic activity with discharges of generalized sharp waves, alternating with phases of lower 
amplitude, moderately slowed activity without epileptiform signals. (B) Follow-up EEG under antiepileptic medication, showing broader transients in now more 
triphasic configuration with more phase lag, alternating with suppressed phases of a now lower amplitude.
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method. Before mounting, slices were counterstained with hema-
toxylin and eosin. The presence of viral antigens was detected in 
the Purkinje cells of the cerebellum (Figure 5A), consistent with 
other confirmed cases of TBEV encephalitis (2). Immunopositive 
cells were also detected in sections of the spinal cord, mostly in 
the anterior horn (Figure 5B).
DIsCUssIoN
The final diagnosis was severe TBE with spinal motor neuron 
injury despite a complete course of vaccination.
An epidemiological study in Switzerland noted that 1,055 TBE 
cases occurred between 2005 and 2011. The average yearly inci-
dence was 2.0/100,000 inhabitants, and 0.7% of these individuals 
died (3). Elaboration of the vaccination history demonstrated 
that in 72% of these cases, individuals were not immunized, and 
in 22% of cases, the immunization history was unknown. Heinz 
et al. (1) assessed the efficacy of vaccination coverage against the 
European subtype of TBE virus in Austria. The authors calculated 
a field effectiveness for a regularly vaccinated person at between 
96 and 99%. Reports on vaccine failures in adequately immu-
nized persons are rare (4). In Switzerland, the vaccine schedules 
consist of three intramuscular injections: at 0, 1–3, and then 
5–12  months after the second vaccine. In European countries, 
there are variations in recommendations regarding the schedule 
of primary and booster vaccinations (5). The role of comorbidity 
(e.g., rheumatoid arthritis) or immunosuppressive drugs in the 
insufficient vaccine response remains unknown in the present 
case (6). Only the last vaccine was administered while the patient 
was under methotrexate treatment. Nonetheless, in patients with 
rheumatoid arthritis, the standard TBEV vaccine schedule may 
not confer enough immunogenicity (7).
The spectrum of clinical manifestations of TBE is broad, rang-
ing from mild meningitis to severe encephalitis. It may be accom-
panied by myelitis and acute flaccid paralysis (8). In patients with 
encephalitis and peripheral neuropathy, the differential diagnosis 
of critical illness neuropathy or Guillain–Barré syndrome is often 
raised. By contrast, in this case, pure motor axonal neuropathy 
was found. This finding was due to anterior horn motoneuron 
damage, which is characteristic of TBE (9) and indicates TBE 
or vaccine failure. However, vaccine failures can be missed if 
antibody titers are measured only in the early phase of the disease 
(4, 10). The combination of a history of a completed course of 
vaccination, the early serology results consistent with vaccination, 
and the rare incidence of vaccine failures markedly delayed the 
diagnosis in this case. The dynamics of the antibody response 
during the course of disease (4, 10) and the molecular diagnostics 
from CNS tissue biopsies are helpful in diagnosing vaccine failure 
cases (11, 12). By contrast, RT-PCR in serum and CSF is typically 
negative when anti-TBEV antibodies are present (12).
In the present case, the vaccine-induced T-cell and antibody 
response failed and subsequently allowed the virus to invade the 
brain parenchyma and the spinal cord. The initial brain biopsy 
revealed a predominant T-cell-driven parenchymal infiltration. 
This finding is in line with other fatal TBE cases (13). We also 
demonstrate the presence of TBEV in the anterior horn of the 
FIGURe 2 | Cerebral magnetic resonance imaging (MRI): (a,B) t2-weighted axial scans. (C) T1-weighted coronal scan after intravenous application of 
gadolinium contrast medium. (D) Coronal scan with fluid attenuated inversion recovery imaging (FLAIR). (a) MRI on day 3. (B–D) MRI on day 16, showing an 
asymmetry with a minimal increase of signal intensity in the left thalamus (B,D) and in the cerebellum, with slight swelling and compression of the cerebellar sulci (D). 
No pathological contrast enhancement was seen (C).
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spinal cord and neurogenic atrophy of the psoas muscle. The his-
topathological picture indicates direct motor ne uron damage by 
the virus and, less dominantly, indirect damage by an inflamma-
tory response. This finding was surprising in light of previously 
hypothesized pathogenic concepts. Gelpi et al. demonstrated that 
immunologic mechanisms contribute to nerve cell destruction in 
human TBE (14). In addition, CD4+ T cells play an important 
role in the TBEV vaccine response (15). An animal infection 
model with lymphocytic choriomeningitis virus demonstrated 
that a vaccine that elicits CD4+ T cells can result in lethal immu-
nopathology following challenge with a persistently replicating 
virus (16). The inflammation found in the tissue of the patient 
was not described to the same extent as in the animal study. The 
possibility of multiple different pathogenetic mechanisms in vac-
cination breakthrough is open to further studies.
Treatment of TBE—irrespective of vaccination status—is 
mainly supportive, including the use of intensive care and assisted 
ventilation when required (8). Because only a limited number of 
cases with vaccine failures are reported, it cannot be concluded 
that they have a more severe clinical course and a poorer 
prognosis. Most published vaccine failures have demonstrated an 
unfavorable course (17–19), but a publication bias is likely. The 
prognosis of TBE is determined not only by meningoencephalitic 
inflammation but also, as shown in this case, by spinal cord dam-
age caused by the virus. This direct damage can result in persistent 
palsy of one or more limbs and even respiratory muscles. In this 
case, motor neuron palsy was generalized with tetraplegia and 
cranial nerve involvement. Complete and generalized motor 
neuron degeneration has no possibility of recovery and indicates 
a very poor prognosis indeed.
CoNCLUsIoN
This case illustrates that TBE can occur despite a full course of 
vaccination. The TBEV vaccine schedule may not provide enough 
cellular immunogenicity in immunocompromised patients. 
Clinicians should keep in mind that detection of specific TBEV 
IgG antibodies in the absence of IgM antibodies at the onset of 
clinical symptoms does not exclude TBE in previously vaccinated 
patients. Pure motor neuropathy is a characteristic finding of TBE 
FIGURe 5 | (a) Immunohistochemical detection of tick-borne encephalitis virus antigen in the cerebellum and (B) in the spinal cord revealed the presence of the 
virus (arrows) in Purkinje cells and in large neurons in the anterior horn. Magnification 100×. Scale bar corresponds to 200 µm.
FIGURe 4 | Histopathological analyses of brain tissue at autopsy. Hematoxylin and eosin-stained section. (a) Parenchymal infiltrates in a widespread 
distribution, multiple foci of lymphocytic meningitis. Magnification 100×. Scale bar corresponds to 200 µm. (B) Infiltrates in leptomeninges. Magnification 400×. 
Scale bar corresponds to 50 µm.
FIGURe 3 | Histopathological analyses of brain biopsy. (a) Images show a mild hypercellularity. (B) Diffuse infiltration by T cells (CD3-positive). (C) Marked 
microglial activation (HLA-DR-positive). Magnification 200×. Scale bar corresponds to 100 µm.
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and should raise suspicion for its diagnosis. The dynamics of the 
antibody response during the course of the disease and PCR from 
CNS samples are helpful to diagnose vaccine failures.
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